[ad_1]
Robbins Geller Rudman & Dowd LLP announces that purchasers of Organogenesis Holdings Inc. (NASDAQ:ORGO) securities between March 17, 2021 and October 11, 2021, inclusive (the “Class Period”) have until this upcoming Tuesday, February 8, 2022 to seek appointment as lead plaintiff in Somogyi v. Organogenesis Holdings Inc., No. 21-cv-06845 (EDNY). Commenced on December 10, 2021, the Organogenesis class action lawsuit charges Organogenesis along with certain of its top executives with violations of the Securities Exchange Act of 1934.
If you suffered significant losses and wish to serve as lead plaintiff of the Organogenesis class action lawsuit, please provide your information by clicking here. You can also contact attorney JC Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Organogenesis class action lawsuit must be filed with the court no later than this upcoming Tuesday, February 8, 2022.
CASE ALLEGATIONS: Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets in the United States. Organogenesis’ products include, among others, “Affinity” and “PuraPly XT.”
The Organogenesis class action…
Full story available on Benzinga.com
[ad_2]
Source link
